A real-world analysis of the clinical and healthcare burden associated with osteogenesis imperfecta
Kenneth I. Berger(New York University), Natalia Petruski‐Ivleva(AVEO Oncology (United States)), Gandarvaka Miles(Sanofi (United States)), Kalyani Hawaldar(IQVIA (United States)), Cemre Robinson(Morristown Medical Center)
Cited by 5
Related Papers
Physiologic Evaluation of the Patient With Lung Cancer Being Considered for Resectional Surgery
|CHEST Journal|2013|901
Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study
|The Journal of Pediatrics|2006|364
Dietary Protein Sources and Risk for Incident Chronic Kidney Disease: Results From the Atherosclerosis Risk in Communities (ARIC) Study
|Journal of Renal Nutrition|2017|254
Respiratory and sleep disorders in mucopolysaccharidosis
|Journal of Inherited Metabolic Disease|2012|158
Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance
|Orphanet Journal of Rare Diseases|2019|114